NEWPORT NEWS, Va., May 1, 2013 PRNewswire/ -- Molecular breast imaging (MBI), also known as breast-specific gamma imaging (BSGI), is a relatively new form of breast cancer detection conducted by injecting the patient in the arm with a specialized tracer and then obtaining images of the tracer distribution using detectors. The imaging procedure is similar to that of mammography, but with significantly less compression and each image takes between 5 10 minutes to obtain. Previous work has established that it can detect cancers missed by mammography, particularly in patients with dense breast tissue however this new research, published earlier this year in the European Journal of Nuclear Medicine and Molecular Imaging, is the largest analysis conducted to date.
(Logo: http://photos.prnewswire.com/prnh/20130501/PH05456LOGO )
Dr. Sun and his research team evaluated hundreds of peer-reviewed articles published on this modality to determine the soundness of the scientific methodology used in each paper. Nineteen papers containing 3,093 patients met their strict criteria for inclusion. Their meta-analysis determined that MBI detected 95% of the cancers overall and that it was particularly useful in: cancers smaller than 1 centimeter, an early stage cancer called ductal carcinoma in-situ, and a type of cancer difficult to detect with mammography called lobular carcinoma with sensitivities of 84%, 88% and 93% respectively. The smallest malignancy detected by MBI was 1mm and it was able to detect breast cancer in 4 of every 100 women who had a negative mammogram. The authors also noted that MBI was as sensitive as breast MRI in the detection of breast cancer, but provided higher specificity (80%) meaning fewer positive results in women without disease. In addition, the MBI procedure can be performed for about 1/3rd the cost of breast MRI and is useful for patients who cannot have an MRI study. Their findings also suggested that similar to breast MRI, MBI can detect additional cancers in 6 of every 100 women who have only one cancer seen by mammography and ultrasound and that it may be useful to help monitor the response of tumors to chemotherapy in patients who are receiving their chemotherapy before breast surgery.
Although the MBI procedure does expose the patient to some radiation, the radiation dose patients receive is similar to that of other diagnostic imaging studies routinely used in medical imaging and there are several researchers looking to reduce the dose even further in order to broaden its use into breast cancer screening. The authors concluded, "Current evidence suggests that BSGI is an extremely useful adjunct to mammography for its ability to identify breast cancer with a high diagnostic performance."
About Dilon Diagnostics®
Dilon Diagnostics®, a brand of Dilon Technologies® Inc., is bringing innovative new medical imaging products to market. Dilon's cornerstone products, the Dilon 6800® and Dilon Acella®, are high-resolution, small field-of-view gamma cameras, optimized to perform Molecular Breast Imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering MBI/BSGI to their patients, such as Cornell University Medical Center, New York and George Washington University Medical Center, Washington, D.C. As part of Dilon's commitment to offering complete solutions, the new declipseSPECT is the first intra-operative handheld 3D image viewing and navigation solution with applications in SLNB breast, I-125 Seed Localization, SLNB Head and Neck etc. For more information on Dilon Technologies® please visit www.molecularbreastimaging.com
Media contact: Pjerin Luli
SOURCE Dilon Diagnostics